SME

IPO ·

NSE SME

Biopol Chemicals Ltd

Listed

Incorporated in 2023, Biopol Chemicals Limited is engaged in the manufacturing and distribution of specialty chemicals categorized into silicones, emulsifiers, biochemicals, and polyelectrolytes.

Issue details

Price band

₹102 – ₹108

Face value

₹10

Lot size

1,200 shares

Minimum investment

₹2,59,200

Issue size

₹31.26 Cr

Fresh issue

₹29.63 Cr

Offer for sale

—

Issue type

Book Built

Exchange

NSE SME

Key dates

Opens

6 Feb 2026

Closes

10 Feb 2026

UPI mandate cut-off

5:00 PM on 10 Feb 2026

Allotment

11 Feb 2026

Refunds

12 Feb 2026

Shares in demat

12 Feb 2026

Listing

13 Feb 2026

Subscription and listing

Subscription

22.26x

Listing price

₹111

Registrar

Bigshare Services Pvt Ltd

Lead manager

Smart Horizon Capital Advisors

Subscription by category

Total

22.26x

Total applications

12,196

Listing day

Issue price

₹108

Open

₹111.00

High

₹111.00

Low

₹105.45

Day close

₹105.50

Listing gain at open

+2.78%

Issue structure

Shares reserved per category and share of the total issue

QIB Shares Offered

6,86,400

23.71%

NII Shares Offered

10,94,400

37.81%

bNII > ₹10L

7,29,600

25.21%

sNII < ₹10L

3,64,800

12.60%

Retail Shares Offered

9,62,400

33.25%

Market Maker Shares Offered

1,51,200

5.22%

Total Shares Offered

28,94,400

100.00%

Finaccle’s quick read

Apply

FY25 income up 182%, PAT up 46%, ROE 36.32%, D/E 0.76, post-issue P/E 14.58x.

A rules-based screen of growth, margins, debt and valuation, built from the offer document and data on Chittorgarh.com. It is for information only and is not investment advice or a recommendation to buy or sell. Read the RHP and speak to a SEBI-registered adviser before you apply.

About the company

Incorporated in 2023, Biopol Chemicals Limited is engaged in the manufacturing and distribution of specialty chemicals categorized into silicones, emulsifiers, biochemicals, and polyelectrolytes. Its product portfolio comprises 66 products, including 40 silicone-based products, 5 emulsifier-based products, 15 biochemical products, and 6 polyelectrolyte products. These products find applications across multiple industries, including textiles, home care, agriculture, and industrial chemicals.

Founded

2023

2023

Promoters

Santanu

Santanu

Promoter holding

89.88% pre-issue; 65.81% post-issue

89.88% pre-issue; 65.81% post-issue

Financial performance

Restated figures in ₹ crore, latest period first

₹ crore, latest first. Full table on desktop.

Period

Total income

Income

EBITDA

PAT

Net worth

Borrowings

Debt

Assets

Dec 2025

Dec 2025

48.97

48.97

8.99

6.00

6.00

19.54

14.92

14.92

48.88

FY25

FY25

49.15

49.15

6.53

4.33

4.33

13.53

7.69

7.69

31.48

FY24

FY24

17.43

17.43

4.43

2.96

2.96

9.20

3.58

3.58

17.56

ROE

36.32%

ROCE

26.32%

Debt / equity

0.76

PAT margin

12.29%

P/E post issue

14.58

Market cap

₹116.70 Cr

Use of IPO money

Acquisition of industrial land

₹12.26 Cr

Repayment or prepayment, in full or in part, of borrowings availed by the Company from banks, financial institutions and non-banking financial companies

₹11.10 Cr

General Corporate Purposes

₹4.04 Cr

Issue Expenses

₹3.85 Cr

Strengths

✓

Revenue up 182% in FY25 to ₹49.15 Cr

✓

PAT up 46% in FY25 to ₹4.33 Cr

✓

PAT margin of 12.29%

✓

ROE of 36.32% and ROCE of 26.32%

✓

Moderate leverage: debt to equity 0.76

Risks to watch

!

SME platform: large lot size and thinner trading liquidity

Planning to take your own company public?

Every listing on this page started with a growing business that got its numbers, governance and paperwork ready for investors. If you are a promoter weighing an SME or main board IPO, we can tell you where you stand and what it will take.

Talk to our IPO Advisory team for readiness planning, or our IPO Consultancy team to run the listing end to end.

Last updated:

Information is compiled from exchange notices and the company’s offer document. It is for general information only and is not investment advice or a recommendation to apply. Read the prospectus before investing.